Stocks and Investing
Stocks and Investing
Fri, May 13, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 12, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Drew Ranieri Maintained (BVS) at Buy with Decreased Target to $11 on, May 12th, 2022
Drew Ranieri of Morgan Stanley, Maintained "Bioventus Inc." (BVS) at Buy with Decreased Target from $18 to $11 on, May 12th, 2022.
Drew has made no other calls on BVS in the last 4 months.
There are 2 other peers that have a rating on BVS. Out of the 2 peers that are also analyzing BVS, 1 agrees with Drew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $17 on, Monday, March 21st, 2022
This is the rating of the analyst that currently disagrees with Drew
- Alexander Nowak of "Craig-Hallum" Initiated at Strong Buy and Held Target at $30 on, Tuesday, March 15th, 2022
Contributing Sources